

References

1. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Semin Liver Dis.* 1995;15:64–69. doi:10.1055/s-2007-1007263.
2. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. *Hepatology.* 1995;22:1027–1033.
3. Tanaka K, Hirohata T, Koga S, et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. *Cancer Res.* 1991;51:2842–2847.
4. Colombo M, de Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med.* 1991;325:675–680. doi:10.1056/NEJM199109053251002.
5. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. *N Engl J Med.* 1993;328:1797–1801. doi:10.1056/NEJM199306243282501.
6. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. *Ann Intern Med.* 2000;132:517–524.
7. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. *Lancet.* 1998;351:1535–1539.
8. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. *Ann Intern Med.* 1998;129:94–99.
9. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. *Hepatology.* 1998;27:1394–1402. doi:10.1002/hep.510270529.
10. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. *Lancet.* 1995;346:1051–1055.
11. Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. *Lancet.* 2001;357:196–197. doi:10.1016/S0140-6736(00)03595-9.
12. Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. *J Hepatol.* 1999;30:653–659.
13. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med.* 1999;131:174–181.
14. Belghiti J, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. *Ann Surg.* 1991;214:114–117.
15. Ikeda K, Arase Y, Kobayashi M, et al. Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a long-term cohort study of 892 patients with viral cirrhosis. *J Gastroenterol.* 2003;38:865–876. doi:10.1007/s00535-003-1163-2.
16. Lam VWT, Ng KKC, Chok KSH, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. *J Am Coll Surg.* 2008;207:20–29. doi:10.1016/j.jamcollsurg.2008.01.020.
17. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. *Hepatology.* 2009;50:1475–1483. doi:10.1002/hep.23181.
18. Okada S, Shimada K, Yamamoto J, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. *Gastroenterology.* 1994;106:1618–1624.
19. Shiina S, Tagawa K, Niwa Y, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. *AJR Am J Roentgenol.* 1993;160:1023–1028.
20. Kubo S, Nishiguchi S, Shuto T, et al. Effects of continuous hepatitis with persistent hepatitis C viremia on outcome after resection of hepatocellular carcinoma. *Jpn J Cancer Res.* 1999;90:162–170.
21. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. *Br J Surg.* 2009;96:975–981. doi:10.1002/bjs.6731.
22. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus-related liver cancer. *Hepatology.* 2000;32:228–232. doi:10.1053/jhep.2000.9409.
23. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. *Br J Surg.* 2002;89:418–422. doi:10.1046/j.0007-1323.2001.02054.x.
24. Kubo S, Nishiguchi S, Hirohashi K, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. *Ann Intern Med.* 2001;134:963–967.
25. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology.* 2006;44:1543–1554. doi:10.1002/hep.21415.
26. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. *J Hepatol.* 2010;52:889–894. doi:10.1016/j.jhep.2009.12.041.
27. Shiratori Y, Shiina S, Teratani T, et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. *Ann Intern Med.* 2003;138:299–306.
28. Singal AK, Freeman DH Jr, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. *Aliment Pharmacol Ther.* 2010;32:851–858. doi:10.1111/j.1365-2036.2010.04414.x.
29. Komorizono Y, Sako K, Yamasaki N, et al. Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy. *Anticancer Res.* 2002;22:3573–3578.
30. Kubo S, Nishiguchi S, Hirohashi K, et al. Influence of previous interferon therapy on recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. *Jpn J Cancer Res.* 2001;92:59–66.
31. Uenishi T, Kubo S, Hirohashi K, et al. Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. *Hepatol Res.* 2002;24:404–412.
32. Uenishi T, Nishiguchi S, Tamori A, et al. Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. *Hepatol Res.* 2006;36:195–200. doi:10.1016/j.hepres.2006.07.011.

33. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatitis C virus ribonucleic acid in the serum by amplification with polymerase chain reaction. *J Clin Invest.* 1990;86:1764–1767. doi:10.1172/JCI114903.
34. Farmer DG, Rosove MH, Shaked A, Busuttill RW. Current treatment modalities for hepatocellular carcinoma. *Ann Surg.* 1994;219:236–247.
35. Lee MJ, Mueller PR, Dawson SL, et al. Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique, and efficacy. *AJR Am J Roentgenol.* 1995;164:215–220.
36. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. *Radiology.* 1999;210:655–661.
37. Seki T, Wakabayashi M, Nakagawa T, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. *Cancer.* 1994;74:817–825.
38. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. *Hepatology.* 2000;32:1224–1229. doi:10.1053/jhep.2000.20456.
39. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. *Gastroenterology.* 2002;123:483–491.
40. Moriyama M, Matsumura H, Aoki H, et al. Long-term outcome, with monitoring of platelet counts, in patients with chronic hepatitis C and liver cirrhosis after interferon therapy. *Intervirol.* 2003;46:296–307. doi:10.1159/000073209.
41. Taniguchi H, Iwasaki Y, Fujiwara A, et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. *J Gastroenterol Hepatol.* 2006;21:281–287. doi:10.1111/j.1440-1746.2006.04201.x.
42. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. *Nat Med.* 1998;4:1065–1067. doi:10.1038/2053.
43. Iwasaki Y, Takaguchi K, Ikeda H, et al. Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy. *Liver Int.* 2004;24:603–610. doi:10.1111/j.1478-3231.2004.0956.x.
44. Imai Y, Tamura S, Tanaka H, et al. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. *J Viral Hepat.* 2010;17:185–191. doi:10.1111/j.1365-2893.2009.01163.x.
45. Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies—a multicenter prospective trial. *J Hepatol.* 2011;54:219–226. doi:10.1016/j.jhep.2010.07.011.

